002262 Jiangsu Nhwa Pharmaceutical
- 24.18
- -0.19-0.78%
Jiangsu Nhwa Pharmaceutical News
Enhua Pharmaceutical (002262.SZ): 2023 equity distribution of 10 distributions of 3.2 yuan Equity Registration Date May 14
Gelonghui, May 7 | Enhua Pharmaceutical (002262.SZ) announced that the company's 2023 equity distribution plan is to distribute RMB 3.20 in cash (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 1,007,588,092 shares. The share registration date for this equity distribution is May 14, 2024, and the ex-dividend date is May 15, 2024.
Is Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Latest Stock Performance A Reflection Of Its Financial Health?
Jiangsu Nhwa Pharmaceutical (SZSE:002262) has had a great run on the share market with its stock up by a significant 12% over the last month. Given that the market rewards strong financials in the l
Enhua Pharmaceutical (002262.SZ): Net profit of 265 million yuan in the first quarter increased 16.64% year-on-year
Gelonghui, April 19 | Enhua Pharmaceutical (002262.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 1,358 million yuan, up 15.16% year on year; net profit attributable to shareholders of listed companies was 265 million yuan, up 16.64% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 267 million yuan, up 16.62% year on year; basic earnings per share were 0.26 yuan.
Is Jiangsu Nhwa Pharmaceutical (SZSE:002262) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Enhua Pharmaceutical (002262.SZ): The new drug NVX-408 project is still in the pre-clinical research stage
Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “Why has the new drug NVX-408 not progressed?” The company replied that the company's new drug NVX-408 project is still in the pre-clinical research stage.
Enhua Pharmaceutical (002262.SZ): The new drug Oselidine Injection (TRV130) achieved sales of around 18 million yuan last year
Gelonghui, April 9丨Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “How much was the new drug R130 sold last year, and how much was the gross profit?” The company replied that the new drug oselidine injection (TRV130) launched by the company achieved sales of around 18 million yuan last year, and the gross margin was slightly higher than the company's anesthetic products.
Enhua Pharmaceutical (002262.SZ): Gabapentin, risperidone, dexmedetomidine, and olanazepine participated in the collection
Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “What products are currently participating in the collection?” The company replied that gabapentin, risperidone, dexmedetomidine, and olanazepam are equal.
Enhua Pharmaceutical (002262.SZ): Protolin nasal spray, an innovative drug to treat Alzheimer's disease, has completed phase I clinical trials and is expected to conduct phase IIa clinical trials in 2024
Gelonghui, April 9, 丨 Enhua Pharmaceutical (002262.SZ) held a performance briefing on April 8, 2024 to discuss “What stage has the company reached in the development of innovative drugs for Alzheimer's disease?” The company replied that up to now, the company's innovative drug Protolin nasal spray to treat Alzheimer's disease has completed phase I clinical trials, and it is expected that phase IIa clinical trials will be carried out in 2024.
Nhwa Pharma Gets Nod to Test NH103 Oxalate Tablets
Jiangsu Nhwa Pharmaceutical (SHE:002262) will conduct clinical trials on NH103 oxalate tablets after receiving approval from China's National Medical Products Administration, the company said in its f
Enhua Pharmaceutical's performance growth during the narcotics iteration period is difficult to change the growth rate “anxiety”
“Investor Network” Cai Jun At the end of March, Enhua Pharmaceutical (002262.SZ, hereinafter referred to as the “Company”), which specializes in narcotics, disclosed its 2023 report. During the reporting period, the company's operating income and net profit attributable to shareholders of listed companies were 5.04 billion yuan and 1,037 billion yuan respectively, up 17.28% and 15.12% year-on-year respectively. On the face of it, the company's performance has maintained a good growth rate. Looking at business breakdown, the growth rate of the pharmaceutical industry (pharmaceuticals) was 14.85%, accounting for 83.71% of revenue. However, there is still a gap between this growth rate and early expectations. At the same time, narcotics are undergoing technological iteration. Earlier, Hisashi
Enhua Pharmaceutical (002262.SZ): NH103 oxalate tablets approved to conduct clinical research on antidepressants
Enhua Pharmaceutical (002262.SZ) issued an announcement. The company recently received approval and issuance from the State Drug Administration...
Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Full-Year Results: Here's What Analysts Are Forecasting For This Year
The full-year results for Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) were released last week, making it a good time to revisit its performance. It looks like the results were a bit of a
Nhwa Pharmaceutical's 2023 Profit Climbs 15% as Revenue Rises 17%
Jiangsu Nhwa Pharmaceutical (SHE:002262) booked a net profit attributable to shareholders of 1.04 billion yuan in 2023, up 15.1% from the year-ago profit of 900.7 million yuan, according to the compan
Benign Growth For Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) Underpins Its Share Price
Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) price-to-earnings (or "P/E") ratio of 20.9x might make it look like a buy right now compared to the market in China, where around half of the compa
Teva Pharmaceutical Investments Singapore, A Subsidiary Of Teva Pharmaceutical Industries And Jiangsu Nhwa Pharmaceutical Formed A Partnership To Market And Distribute Teva's Austedo (Deutetrabenazine) For Neurodegenerative And Movement Disorders
Teva Pharmaceutical Investments Singapore, A Subsidiary Of Teva Pharmaceutical Industries And Jiangsu Nhwa Pharmaceutical Formed A Partnership To Market And Distribute Teva's Austedo (Deutetrabenazine
Private Companies Account for 32% of Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Ownership, While Institutions Account for 25%
Key Insights The considerable ownership by private companies in Jiangsu Nhwa Pharmaceutical indicates that they collectively have a greater say in management and business strategy A total of 5 inves
Enhua Pharmaceutical (002262.SZ) passed the high-tech enterprise review
Gelonghui, February 6, 丨 Enhua Pharmaceutical (002262.SZ) announced that recently, the company successfully passed the high-tech enterprise review and received the “High-tech Enterprise Certificate” jointly issued by the Jiangsu Provincial Department of Science and Technology, the Jiangsu Provincial Department of Finance, and the Jiangsu Provincial Taxation Bureau of the State Administration of Taxation. Certificate number: GR202332012741, date of issue: December 13, 2023, valid for three years.
Jiangsu Nhwa Pharmaceutical (SZSE:002262) Sheds 9.3% This Week, as Yearly Returns Fall More in Line With Earnings Growth
Jiangsu Nhwa Pharmaceutical Co., LTD (SZSE:002262) shareholders might be concerned after seeing the share price drop 14% in the last month. But that scarcely detracts from the really solid long ter
Jiangsu Nhwa Pharmaceutical (SZSE:002262) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Enhua Pharmaceutical (002262.SZ): Fentanyl citrate injection passed generic drug consistency evaluation
Gelonghui, January 3 | Enhua Pharmaceutical (002262.SZ) announced that the company recently received the “Drug Supplement Application Approval Notice” for fentanyl citrate injections approved and issued by the State Drug Administration, which approved the drug to pass the consistent evaluation of generic drug quality and efficacy. Fentanyl citrate injection is a potent analgesic. It is suitable for sedation and analgesia before, during, and after anesthesia. It is currently a commonly used drug in complex general anesthesia. The company has invested about 2.1 million yuan in R&D expenses in the product's consistency evaluation project.
Analysis
Price Target
No Data
